ByrneWallace has one of the leading corporate practices in Ireland. Our Corporate Group is one of the firm's core practice areas and provides a dynamic, committed and experienced service to domestic and international clients across a wide range of sectors. Our client-focused approach and understanding of our clients’ business is crucial to our success. We combine commercial acumen, extensive experience and technical expertise with a solutions-driven approach.
We advise businesses at every stage of development from establishment to early-stage fundraising, through expansion, equity and debt financing to restructuring, acquisition or listing across the full spectrum of corporate transactions and structures.
Our energetic and innovative team is widely known for its capacity to tackle even the most complex transactions in a client-focused, innovative and approachable manner. Our partners are trusted business advisers as well as first-rate legal practitioners and bring to the table sectoral-specific experience from a broad range of industry sectors, including finance, technology, life sciences, pharmaceuticals, energy, healthcare, food and drink, retail and the public sector.
The expertise of our Corporate Group is seamlessly complemented by specialist input from dedicated practice areas such as commercial contracts, banking and finance, intellectual property, tax, employment, property, commercial litigation and competition and regulatory law.
Our Corporate Group advises on:
- Equity Capital Markets, including IPOs and secondary placings
- Mergers & Acquisitions – Public and Private
- Inversions and Corporate Migrations
- Corporate Structuring and Re-Organisations
- Corporate Finance – Private Equity and Venture Capital Investments
- Leveraged Buy-Outs
- Shareholder and Joint Venture Arrangements
- Partnerships and other Corporate Structures
- Corporate Governance and Compliance
- Corporate Advisory
Please click here for our recent publications on the regulatory changes introduced by the Companies Act, 2014.
ByrneWallace advise Inflazome Limited in relation to its €40 million Series B Financing to develop NLRP3 inflammasome inhibitors to clinical proof-of-concept.
ByrneWallace advise Brindley Healthcare on its acquisition of Kilminchy Lodge Nursing Home